What happens when you stop a GLP-1: the weight comes back as the wrong tissue

The prescription is doing its job. Appetite is quiet, the scale is finally moving, and for the first time in years eating feels like a decision rather than a war. So the question nobody wants to sit with feels almost ungrateful: what happens the week you stop.

The comfortable assumption is that weight loss is like paying down a debt. You do the hard part once, the weight is gone, and now you simply maintain from a lower starting point. That is how dieting is supposed to work in the stories we tell ourselves. The trials that followed people after they came off these drugs tell a colder story, and it is worth reading before you are standing at the pharmacy counter deciding whether to refill.

The honest version is this. A GLP-1 medication buys you a window in which losing weight is unusually easy, because the drug is doing the appetite work for you. What it does not buy is a new set of habits. If the weeks on the medication were spent losing weight and nothing else, then stopping tends to hand a large share of that weight straight back. The insurance policy against that outcome is not a better drug. It is a training habit and an eating pattern that are still standing on the day the prescription runs out.

This piece is education, not medical advice. Nothing here is a reason to start, continue or stop a medication. That decision belongs with your doctor, and for many people staying on a GLP-1 long term is the right, appropriate call, in the same way someone stays on medication for blood pressure. The point of this article is narrower: to be clear-eyed about what the withdrawal data shows, and to make the case that the behaviours you build during treatment are what determine where you end up after it.

Build the habit half with Pocket Fit. It installs the training routine and tracks the protein that decide what stays when the medication stops. Free on the App Store and Google Play, no card needed.

The regain is not a rumour, it is the trial design

Start with the cleanest evidence, because this is the part people are least prepared for. When researchers ran the STEP 1 trial of semaglutide, they did not just measure the weight loss. A group of participants was followed for a full year after the drug and the lifestyle support were stopped, and the results were published by Wilding and colleagues in Diabetes, Obesity and Metabolism in 2022.

The numbers are stark and specific. On the medication, participants lost an average of 17.3 percent of their body weight. One year after stopping, they had regained 11.6 of those percentage points, leaving a net loss of just 5.6 percent from where they started. In plain terms, participants regained about two-thirds of everything they had lost within twelve months of the last dose. Blood pressure, blood sugar and cholesterol drifted back toward baseline alongside the weight. The authors' conclusion was blunt: obesity behaves like a chronic condition, and maintaining the improvement appears to require ongoing treatment.

That is one trial, but it is not alone. The STEP 4 trial, reported by Rubino and colleagues in JAMA in 2021, was built specifically to test what stopping does. Everyone took semaglutide for a 20-week run-in, then half were quietly switched to a placebo. Over the following 48 weeks the group that kept taking the drug lost a further 7.9 percent, while the group switched to placebo regained 6.9 percent. Same people, same starting point, and the only thing that changed was whether the drug was still on board.

The newer drugs regain too

It would be easy to assume this is an old-molecule problem that the newer, stronger drugs have solved. They have not. Tirzepatide, the dual GLP-1 and GIP medication, is the most effective weight-loss drug widely available, and it shows the same withdrawal pattern.

The SURMOUNT-4 trial, published by Aronne and colleagues in JAMA in 2024, used the same design. Participants took tirzepatide for 36 weeks, losing a striking average of 20.9 percent of body weight, and were then randomised either to continue or to switch to placebo. Over the next year, those who continued lost a little more. Those switched to placebo regained 14 percent of their body weight. The gap between staying on and coming off came to more than 19 percentage points.

Read the three trials together and the message is consistent across molecules and across years of research. These drugs produce large, genuine weight loss, and that loss is largely conditional on continuing to take them. This is not a mark against the medication. It is simply how appetite-suppressing drugs work: remove the suppression and, for most people, appetite and the old eating patterns return. The drug was never a cure that you complete. It is a tool that works while it is in use.

Why coming back to the same weight is not coming back to the same body

Here is the part that turns a story about weight into a story about your body, and it is where you have to reason carefully rather than point at one clean trial.

Weight lost on a GLP-1 is not purely fat. As covered in detail in the muscle you lose on a GLP-1, body-composition sub-studies of these trials consistently show that a meaningful share of the weight that comes off is lean mass. In the STEP 1 scan analysis, lean tissue accounted for roughly 40 percent of the total lost; with tirzepatide the picture was kinder, at around a quarter. Either way, muscle leaves alongside the fat, because rapid weight loss of any kind takes some muscle with it, and a suppressed appetite makes it hard to eat the protein that would defend it.

Now follow what happens on the way back up. When people regain weight after stopping any diet or drug, the regained tissue is disproportionately fat. Muscle does not automatically rebuild just because the weight is returning; rebuilding muscle requires a specific stimulus, namely resistance training and adequate protein, and it is slow work that gets slower with age. So the two directions are asymmetric. You lose a mix of fat and muscle on the way down, and you regain mostly fat on the way up.

Put those two facts side by side and the concern writes itself. Someone can complete a full cycle - lose 20 kilos on the drug, come off, regain 13 of them - and arrive back near a similar weight carrying more fat and less muscle than when they began. The scale would call that roughly a draw. Body composition would call it a loss. This is the outcome the rest of this article is about avoiding, and I want to be honest that it is a reasoned concern built from the fat-versus-lean regain pattern in the evidence, not a single headline trial that scanned people through a complete stop-and-regain cycle. The direction is well supported. The exact size of the effect for any one person is not something the current trials pin down.

Protect the muscle with Pocket Fit. It builds the resistance training and tracks the protein that decide whether regained weight finds you weaker. Free on iOS and Android.

Where the evidence is strong and where it runs thin

This is the section most articles on this subject skip, so let me be straight about what these numbers can and cannot carry.

What is strong is the regain itself. Three separate randomised trials, across two drug classes, all show substantial weight return after stopping, and STEP 4's withdrawal design makes the causal link about as clean as clinical research gets. If you take one thing as settled, take this: for most people, the weight loss lasts about as long as the medication does.

What is softer is the body-composition half of the argument. The lean-mass losses come from DXA sub-studies of a few hundred people, not the headline trials, and DXA cannot perfectly separate muscle from water and other lean tissue, so the exact percentages are strong estimates rather than fixed constants. More importantly, no large trial has scanned people through a full cycle of loss on the drug and regain after stopping to confirm precisely how much of the regain is fat versus muscle in this specific population. The fat-skewed regain pattern is well established in the broader weight-loss literature, which is why it is a fair thing to reason from, but treat it as a well-grounded expectation rather than a measured result.

And one more honest caveat. Almost none of these drug trials had participants following a structured resistance-training and high-protein plan. They largely captured what happens on ordinary lifestyle advice. That is precisely the gap the next section is about. The regain figures are close to a worst case for someone who trained nothing, not a fixed destiny for someone who did.

The one thing that predicts keeping it off

If stopping tends to bring weight back, the useful question is what separates the people who keep it off from the people who do not. Here the research is unusually consistent, and it has been for decades.

The National Weight Control Registry has tracked thousands of people who lost significant weight and kept it off for years. When Wing and Hill summarised what those successful maintainers had in common, in the Annual Review of Nutrition in 2001, the same behaviours came up again and again: they monitored their weight and food, they ate in a consistent pattern, and above all they were physically active at a high level. Registry members average close to an hour of activity a day. High physical activity is one of the strongest and most durable predictors of keeping weight off that the maintenance literature has.

Notice what this is really saying. Weight maintenance is not held in place by the thing that produced the loss. It is held in place by ongoing behaviours. A drug that suppresses appetite is a superb way to produce a loss, but it is not a behaviour, and the day it stops it stops being one. The people who maintain are the people who, drug or no drug, kept moving and kept eating in a way they could sustain. That is the habit the medication window is for.

What to build while the drug is doing the appetite work

The strategic point is almost the opposite of how the window usually gets used. Motivation is never higher and never cheaper than while a GLP-1 is quietly killing your appetite for you. That is the moment to spend building the habits, not the moment to coast on easy weight loss. A short list of what actually earns its place:

• Resistance training two to three times a week. This is the non-negotiable one, because it is the only signal that tells your body to keep muscle while you lose weight, and later the only thing that rebuilds it. It is also the behaviour most strongly tied to keeping weight off.
• Protein anchored at every meal. A suppressed appetite drags total intake down by default, and protein is usually the first casualty. Hitting a protein target on purpose is what gives the training something to work with. The protein and progressive overload piece covers why.
• Getting genuinely stronger, not just going through the motions. Adding reps and then load over the weeks - reps first, then weight - is what turns showing up into strength you actually keep.
• A pattern of eating you could run without the drug. If your current way of eating only works because appetite is switched off, it is not a habit yet. The window is the time to practise the version that survives.

None of this requires heroics. It requires the training to happen on a schedule while the appetite side is handled, so that the routine is automatic by the time you might come off. As covered in calorie deficit and strength training, losing weight and building the strength habit are not competing tasks; they are meant to run together.

Where Pocket Fit fits

Pocket Fit does not touch your medication and makes no claim to. What it does is the other half - the half the trials mostly left out.

The programme builds your resistance training for you, week to week, so the decision of what to do on any given day is already made. That matters more than it sounds, because the failure mode is rarely a lack of willpower while the drug is doing the appetite work; it is friction, the small daily question of what to train that quietly ends routines. How Pocket Fit builds your program walks through how the split is chosen. The Body budget keeps a running tally of the deposits that actually compound - your workout, your streak, your sleep and your nutrition - so the habit is visible rather than a matter of memory. The Fuel tool lets you scan a plate or a barcode and check protein against a target, no red numbers and no shame, which is how you catch the protein gap a suppressed appetite hides. And the scheduler reshuffles a missed session into the rest of the week rather than letting one skip become a lapse.

The framing that matters is this. Motivation is easy while the drug is carrying the appetite. The entire job of that window is to still be training on the day the prescription ends, because that day is when the habit stops being optional and starts being the only thing holding your result in place. Building that habit without the punishment of a strict app is the point of accountability without shame.

This is not an abstract worry for the person who built Pocket Fit. Georgi went from 122 kg to competing at The Yard Games, and the app exists because of the bad weeks, the ones where the plan has to survive a life that does not cooperate. That story is on our story. The through-line is the same whether or not a medication is involved: the result is decided by the behaviour that outlasts the easy stretch.

Start with Pocket Fit, free. Build the training habit and the eating pattern that stay when the medication stops. Personalised in minutes on iOS and Android.

GLP-1 weight regain: common questions

Will I definitely regain the weight if I stop a GLP-1?

Not definitely, but the odds are against you if nothing else changed. Across the STEP 1 extension, STEP 4 and SURMOUNT-4 trials, most participants regained a large share of the lost weight after stopping - about two-thirds within a year in the STEP 1 follow-up. Those trials mostly did not include structured training and a high-protein plan, so their figures reflect what happens without those habits. The behaviours you build during treatment are what shift the odds.

Should I stop taking my GLP-1?

That is a medical decision, and it belongs entirely with your doctor, not with an app or an article. Obesity behaves like a chronic condition, and for many people staying on the medication long term is the appropriate choice. Nothing here is a reason to stop. The message is only that if you and your doctor do plan a stop, the habits you have built will matter enormously.

Why can I end up in worse shape at the same weight?

Because the tissue is not symmetric. Weight lost on a GLP-1 is a mix of fat and muscle, but weight regained after stopping is disproportionately fat, since rebuilding muscle needs resistance training and protein rather than just returning calories. Complete a full loss-and-regain cycle without training and you can land at a similar weight carrying more fat and less muscle than before. This is a reasoned concern from the fat-versus-lean regain pattern, not a single measured trial result.

What is the single most important habit to build?

Resistance training, two to three times a week. It is the only signal that tells your body to hold onto muscle while you lose weight and the only thing that rebuilds it afterward, and high physical activity is one of the strongest predictors of long-term weight maintenance in the research. Protein at every meal is the close second, because it gives the training something to work with.

Does the app treat or interact with my medication?

No. Pocket Fit is a fitness and wellbeing app, not a medical device, and it does not diagnose, treat or affect any medication. It handles the training and nutrition side only - the behaviours that determine what stays after weight loss. Anything to do with the medication itself is between you and your healthcare professional.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. DOI: 10.1111/dom.14725
2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414-1425. DOI: 10.1001/jama.2021.3224
3. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38-48. DOI: 10.1001/jama.2023.24945
4. Wing RR, Hill JO (2001). Successful Weight Loss Maintenance. Annual Review of Nutrition, 21, 323-341. DOI: 10.1146/annurev.nutr.21.1.323

---

Pocket Fit is a fitness and wellbeing app, not a medical device. It does not diagnose, treat or prevent any condition. Always consult a qualified healthcare professional before starting or changing a training or nutrition programme, and if you have persistent problems with sleep, pain or fatigue.

Georgi, founder of Pocket Fit. He went from 122 kg to competing at The Yard Games, having lost 38 kg along the way.